British Journal of Haematology

British Journal of Haematology is a peer-reviewed medical journal covering clinical and laboratory haematology. It publishes original research, reviews, guidelines, and correspondence, serving clinicians and investigators in haematology, oncology, transfusion medicine, and stem cell biology. The journal interfaces with professional bodies, research institutes, university departments, and healthcare organizations across Europe, North America, Asia, and Australasia.

History

The journal was founded in 1955 and developed alongside postwar institutions such as the National Health Service and academic centres at University of Oxford, University of Cambridge, King's College London, and University College London. Early editors collaborated with societies like the British Society for Haematology and international organizations including the European Hematology Association and the American Society of Hematology. Over decades the journal documented advances linked to landmark figures and projects such as William Dameshek, Max Perutz, Howard Florey, and the emergence of treatments influenced by trials at Mayo Clinic, Memorial Sloan Kettering Cancer Center, and Fred Hutchinson Cancer Center. The publication tracked developments from classical studies of haemoglobinopathies tied to research at Addenbrooke's Hospital and Great Ormond Street Hospital to molecular genetics shaped by laboratories at the Wellcome Trust Sanger Institute and the Francis Crick Institute.

Scope and Content

The journal covers clinical trials, translational research, case series, and consensus guidelines relevant to entities such as acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma, thalassemia, sickle cell disease, hemophilia, and immune thrombocytopenia. It publishes work on laboratory techniques developed in centres like Institut Pasteur, Max Planck Institute, Riken, and Cold Spring Harbor Laboratory, and on therapeutics tied to pharmaceutical companies such as Roche, Novartis, Bristol-Myers Squibb, Gilead Sciences, and Pfizer. Reviews often cite guideline-making bodies including National Institute for Health and Care Excellence, European Medicines Agency, and World Health Organization. The content spans diagnostics influenced by technologies from Illumina, Thermo Fisher Scientific, and Oxford Nanopore Technologies, to cellular therapies such as chimeric antigen receptor T-cell approaches pioneered at University of Pennsylvania and trials coordinated with European Society for Blood and Marrow Transplantation.

Editorial and Publication Details

The editorial board has historically included clinicians and scientists affiliated with institutions like St Bartholomew's Hospital, Royal Free Hospital, Johns Hopkins Hospital, Massachusetts General Hospital, and Karolinska Institutet. The publisher, operating in partnership with academic societies and professional groups, manages peer review processes similar to practices at journals like The Lancet, New England Journal of Medicine, and Nature Medicine. The journal issues thematic supplements and special editions featuring consensus statements produced with contributors from American Society of Clinical Oncology, European League Against Rheumatism, and national blood services such as NHS Blood and Transplant and American Red Cross Blood Services. Editorial policies align with standards promoted by organizations including Committee on Publication Ethics and indexing requirements of PubMed Central, Scopus, and Web of Science.

Abstracting and Indexing

The journal is indexed in major bibliographic databases and citation indexes used by researchers at institutions like Harvard University, Stanford University, University of California, San Francisco, Yale University, and Imperial College London. It appears in services operated by providers such as Clarivate Analytics and Elsevier and is discoverable via library consortia at British Library, Library of Congress, and national libraries across Europe and Asia. Abstracting includes integration with specialist haematology resources and guideline repositories maintained by European Centre for Disease Prevention and Control and academic networks including ClinicalTrials.gov collaborators.

Impact and Reception

The journal's impact factor and citation metrics are monitored alongside peer publications such as Blood, Haematologica, and Leukemia. Influential articles have been cited in policy documents from bodies like National Institute for Health and Care Excellence and trial reports originating from multicentre collaborations involving European Organisation for Research and Treatment of Cancer, Children's Oncology Group, and International Bone Marrow Transplant Registry. The readership includes haematologists trained at centres like Mount Sinai Hospital, Cleveland Clinic, and Royal Marsden Hospital, and the journal is referenced in educational curricula at universities such as University of Edinburgh and University of Glasgow. Critical appraisal by researchers from institutions including Johns Hopkins University School of Medicine and commentators in outlets like BMJ and Nature contribute to its standing in the field.

Category:Haematology journals